These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33015652)

  • 21. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.
    Hartman WR; Hess AS; Connor JP
    Transfusion; 2020 Oct; 60(10):2189-2191. PubMed ID: 32533556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions.
    Bonetti TCS; Latini FRM; Invitti AL; Fonseca MCM; Scorza FA; Saldanha MG; Bellucco FT; Bacarov NBS; Soane MM; Girão MJBC
    Clinics (Sao Paulo); 2021; 76():e2818. PubMed ID: 34468538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
    Chibwana MG; Moyo-Gwete T; Kwatra G; Mandolo J; Hermanaus T; Motlou T; Mzindle N; Ayres F; Chaponda M; Tembo G; Mwenechanya P; Mitole N; Jassi C; Kamng'ona R; Afran L; Mzinza D; Mwandumba HC; Gordon SB; Jere K; Madhi S; Moore PL; Heyderman RS; Jambo KC
    BMC Med; 2022 Mar; 20(1):128. PubMed ID: 35346184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.
    Yang W; Kandula S; Huynh M; Greene SK; Van Wye G; Li W; Chan HT; McGibbon E; Yeung A; Olson D; Fine A; Shaman J
    Lancet Infect Dis; 2021 Feb; 21(2):203-212. PubMed ID: 33091374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
    Ranganathan S; Iyer RN
    Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests.
    Rak A; Donina S; Zabrodskaya Y; Rudenko L; Isakova-Sivak I
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
    Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW;
    N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: A transversal surrogate in vitro study performed in Quito-Ecuador.
    Villacrés-Granda B; Paz E; Burbano MJ; Villacrés-Granda I; Armijos D; Aguirre M
    J Med Virol; 2022 Sep; 94(9):4246-4252. PubMed ID: 35585654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a SARS-CoV-2 RNA RT-PCR assay for high-throughput testing in blood of COVID-19 convalescent plasma donors and patients.
    Strasser EF; Steininger PA; Korn K; Achenbach S; Tenbusch M; Cunningham S; Zimmermann R; Überla K; Hackstein H
    Transfusion; 2021 Feb; 61(2):368-374. PubMed ID: 33125162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
    Lancman G; Mascarenhas J; Bar-Natan M
    J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.
    González-Stegmaier R; Cereceda K; Briones JL; Beltran-Pávez C; Oyarzún-Arrau A; Riquelme-Barrios S; Selman C; Yarad F; Mahave M; Caglevic C; Morales R; Aguirre A; Valiente-Echeverría F; Soto-Rifo R; Marsiglia H; Gazitua R; Villarroel-Espindola F
    J Immunol Res; 2021; 2021():6680337. PubMed ID: 33644235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.